OncoPrecision

health AImedtechoncology therapeutics

Visit website LinkedIn ↗

StageSeed VC

YC batchIndieBio (accelerator)

Raised$10.2M to $15.6M

Founded2020

Employees17

LocationNew York, NY

Business modelB2B, B2B2C, SaaS (discovery engine elements)

About

OncoPrecision is a precision oncology company engineering first-in-class antibody-drug conjugates (ADCs) and bispecific antibodies for hard-to-treat cancers. We start where other drugs fail — studying how cancer cells evade treatment — then engineer precision weapons to exploit those vulnerabilities. By combining our Patient Micro-Avatars™ with AI-driven target validation across billions of phenotypic data points, our discovery engine surfaces biology that population-level datasets miss — giving every program a structural advantage from day one. Our lead program, ONC001, is a first-in-class CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages. ONC001 is currently advancing through IND-enabling studies.

Product

Value proposition: OncoPrecision is an oncology therapeutics company developing precision medicines guided by real patient biology, leveraging AI-driven discovery and patient-derived models to create targeted therapies with higher probabilities of clinical success.
Target customers: Pharma/Biotech companies, research partners, healthcare providers seeking precision oncology therapeutics

Founders

Candelaria Llorens De Los Ríos — Co-Founder & Head of Operations
Gastón Soria — Co-Founder & CSO
Gerardo Gatti — Co-Founder & Head of Clinical Research
Tarek Ali Zaki — Co-Founder & CEO

Products

ONC001 (first-in-class ADC)Patient Micro-Avatars (PMAs)AI-enhanced target validation platformAntibody-drug conjugates (ADCs)bispecific antibodies (BsAbs)

Key features

Patient-derived biology as the primary target sourceAI-driven target validationPMAs translational models from real patient samplesADC/BsAb development targeting CD64convergence of patient biology, AI, and first-in-class design

Technologies

AI/machine learningcomputational modelingantibody-drug conjugatesbispecific antibodiesPatient Micro-AvatarsTMtranslational modelsbiomarker-driven discovery

Target conditions

Blood cancershard-to-treat solid tumorsCMMLacute monocytic leukemia (AML)tumor-associated macrophage activitycancer that evades standard therapy

Care settings

hospitalclinicresearch labstranslational/academic partnerships

News

Org of the Week: OncoPrecision | The Org · 2025-04-22T16:00:00.000Z
OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting · 2025-12-01T15:17:00.000Z
OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting · 2025-12-01T15:17:00.000Z
[PDF] Ecosystem Report 2025 - Startup Genome
OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting · 2025-12-01T15:17:00.000Z

Browse similar startups

Related startups

Oncoscope — New York, NY
Optio.ai Inc. — New York City, NY
Ovaterra™ — New York, NY
Phenotap — New York, NY
Plinth Analytics — New York, NY
Precise Diagnostic & Imaging — Brooklyn, NY
Oncospace — Baltimore, MD
OncoSys AI — Cambridge, MA
Onduo by Verily — Newton, MA
OnPoint Vision, Inc. — Aliso Viejo, CA
ONSLOW RADIATION ONCOLOGY LLC — Jacksonville, NC
Ontogen Medtech — Lisle, IL

Profile updated Jul 29, 2026. Sources: oncoprecision.bio, linkedin.com